Recent Conference Coverage
Physical exercise may have a direct effect on cancer that is as effective as drugs for treating patients with prostate cancer, even for those with advanced stages of the disease.
Disparities in cancer risk management among BRCA carriers across a diverse sample of young black, Hispanic, and non-Hispanic white breast cancer survivors underscores that "the benefit from genetic testing comes from acting on the test results," not just the testing itself, a study presented at the ASCO 2016 Annual Meeting concluded.
Multiplex gene testing of diverse patients has found that patients who test positive advise relatives to test, "suggesting that participants understood the implications of test results," according to results of a planned interim analysis of a prospective trial presented at the ASCO 2016 Annual Meeting.
"In the absence of patient-matched germline data, large germline databases are required in analysis workflows to minimize false positive mutation calling and mitigate ethnic disparities," a study presented at the ASCO 2016 Annual Meeting concluded.
Results showed that telephone disclosure was not worse than in-person disclosure for general and state anxiety.
"Patients who feel better, live longer." And, to help patients feel better, clinicians need to provide optimal symptom management, said Eric Roeland, MD, GI Oncology & Palliative Care, UC San Diego Moores Cancer Center, San Diego, California, discussant for 4 poster presentations at the ASCO 2016 Annual Meeting.
Final analysis of data from the phase 3 KEYNOTE-006 presented at the ASCO 2016 Annual Meeting confirm the superiority of pembrolizumab over ipilimumab for advanced melanoma.
At 3 years, 40% of patients with advanced melanoma treated with pembrolizumab are alive regardless of whether they had been treated with ipilimumab or not, follow-up results from the KEYNOTE-001 study reported at the ASCO 2016 Annual Meeting.
The longest overall survival follow-up among randomized phase 3 trials evaluating BRAF and MEK inhibitors in patients with BRAF-mutant metastatic melanoma to date has shown the best 3-year outcome with dabrafenib plus trametinib to be in patients with normal LDH and fewer than 3 disease sites, according to a presentation at the ASCO 2016 Annual Meeting.
Binimetinib may represent a new effective therapy for patients with NRAS-mutant melanoma, both before and after immunotherapy. That is the conclusion of the phase 3 NEMO study, results of which were presented at the ASCO 2016 Annual Meeting.
A nurse-facilitated oral chemotherapy care model has improved delivery times, patient satisfaction, and co-pay support at a Connecticut cancer hospital.
Follow-up telephone calls and clinician assessment may be an effective strategy to identify early which patients require support with adhering to oral cancer therapy.
A nurse-managed precision cancer treatment education resource center may improve information dissemination about genomic health and targeted therapy.
Instituting a Chemotherapy Safety Committee and developing an administration process successfully standardized the inpatient oral chemotherapy administration process.
A formal nursing practice was developed to promote patient safety and adherence with oral chemotherapy.
Implementation of the Massey Bedside Swallowing Screen and strict oral care regimens in high-risk patients reduced the rate of hospital-acquired pneumonia (HAP) at an oncology treatment center.
A central venous catheter self-management education program is an effective nursing intervention to promote long-term self-management of a CVC for discharged patients with cancer.
The formation of a multidisplinary taskforce and the introduction of improved products successfully reduced the rates of catheter associated urinary tract infections (CAUTI) at an oncology hospital.
Daily chlorhexidine gluconate bathing on all patients with ports and tunneled catheters decreased the rates of CLABSI on an inpatient oncology unit.
Formation of a multidisciplinary team and a focus on evidence-based interventions successfully reduced the rate of central line bloodstream infections (CLABSI) on an inpatient oncology unit.
The multikinase inhibitor regorafenib significantly improved overall survival rates compared to placebo in patients with hepatocellular carcinoma, according to data from the phase 3 RESORCE trial.
CT-Based Technique for Body Mass Measurements of Patients With Cancer Improves Disease Staging, Therapy Monitoring
A new method of measuring lean body mass accounts for changes in body composition, enabling improved disease staging and monitoring of therapy.
Ibrutinib treatment for chronic lymphocytic leukemia with the deletion of chromosome 17p (del17p CLL) increases the percentage of patients alive at 30 months over other therapies for del17p CLL.
Including an antiemetic in the preprocedure medications for patients with liver cancer undergoing drug eluting bead chemoembolization (DEB TACE) can shorten hospital stays and reduce the chance for readmission due to complications.
Results from phase II trial on the use of FDG-PET to evaluate the efficacy of an immunotherapy drug in the treatment of NSCLC.
Event-free survival for adult patients with ALL has improved from 40% to 73% with the implementation of the NOPHO ALL 2008 protocol in July 2008.
Deep and durable remissions were produced by the combination of SGN-CD33A and hypomethylating agents among patients with acute myeloid leukemia (AML).
Overall survival for patients with acute lymphoblastic leukemia (ALL) was nearly doubled to 7.8 months from 4.0 months by treating patients with blinatumomab compared with standard of care.
Daratumumab in Combination With Standard-of-Care Treatment Significantly Improves Outcomes in Patients With Multiple Myeloma
Daratumumab in combination with the standard-of-care treatment regimen reduced risk of disease progression or death by 63% compared with the standard-of-care regimen alone in patients with multiple myeloma who had received at least 1 prior line of therapy.
Reasons for the continuing increase in cases of young-onset colorectal cancer, despite a decline in the overall rate of the disease in recent years, are unclear.
- Gene Expression Alters Bone Marrow Environment in MGUS, Leading to Multiple Myeloma
- How Can We Have a Cancer Cure Moonshot if We're Short of Fuel?
- High-Fat Mediterranean Diet Can Protect Against Cancer
- Prophylactic Gynecologic Resections Increase Risk for Aggressive Uterine Cancer in BRCA Gene Mutation Carriers
- HPV Vaccination Program Reduces Cervical Cell Anomalies in Young Women
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Blood Biomarker Is Predictive of Risk for Colon Cancer Recurrence
- Hypermutated Hotspots Are Biomarkers Predictive of Better Outcomes in Breast Cancer
- Helical APBI Delivers Targeted Dose of Adjuvant Radiation Treatment for Breast Cancer
- Cancer Risk Higher in Patients With Heart Failure After a First Heart Attack
- Routine Pap Smears Improve Cervical Cancer Risk in Women Older Than 65 Years
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|